| Literature DB >> 33118723 |
Thomas Theologou1, Amer Harky1, Matthew Shaw1, Hazim Eltyeb1, Walid Elbakbak1, Mostafa Snosi1, Deborah Harrington1, Manoj Kuduvalli1, Aung Oo1, Mark Field1.
Abstract
OBJECTIVE: To describe our experience of nine patients with extra-anatomical bypass for clinically ischemic distal limb during repair of acute Type A aortic dissection (ATAAD).Entities:
Keywords: Amputation; Aneurysm, Dissection; Early Diagnosis; Extremities; Ischemia; Peripheral Vascular Diseases; Referral and Consultation; Surgeons
Year: 2020 PMID: 33118723 PMCID: PMC7598955 DOI: 10.21470/1678-9741-2019-0259
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Characteristics of the nine patients operated with femorofemoral bypass.
| Important notes | Cannulation | Leg site | Complications | Notes | ||
|---|---|---|---|---|---|---|
| 1 | M | Bovine arch | Left ventricular cannulation | Ischemic left leg | - | Tamponade |
| 2 | M | Normal arch | Right axillary cannulation | Ischemic right leg | - | |
| 3 | F | Bovine arch | Right femoral cannulation | Ischemic left leg | Fasciotomy | |
| 4 | M | Normal arch | Right axillary cannulation | Ischemic right leg | Paraparesis, reoperation for bleeding from the femoral bypass | |
| 5 | M | ? Marfan | Right axillary cannulation | Ischemic right leg | Right kidney was already ischemic on presentation | |
| 6 | M | Wegener's granulomatosis | Direct true lumen cannulation | Ischemic right leg | ||
| 7 | F | Delay of presentation | Innominate artery cannulation | Both legs were ischemic | Left leg amputation | Axillary artery dissected |
| 8 | F | Delay of presentation | Right axillary & femoral cannulation | Both legs were ischemic | Had bowel ischemia, laparotomy & colostomy, bilateral AKA, fasciotomies | Presented with paraesthesia in both legs, paraplegia, and metabolic acidosis |
| 9 | F | Normal arch | Right axillary cannulation | Ischemic left leg | Had CABGX2 | Persistent leg ischemia despite femorofemoral bypass, so axillobifemoral bypass was performed |
AKA=above-knee amputation; CABGX2=two coronary artery bypass graftings; F=female; M=male
Patients' demographics, co-morbidities, and operative details.
| Variables | All acute Type A dissections | All femoro-femoral bypasses |
|---|---|---|
| (n=181) | (n=9) | |
| Age at operation (years) | 61 (52-70) | 44 (41-55) |
| Female gender | 61 (33.7%) | 4 (44.4%) |
| Comorbidities | ||
| Body mass index (kg/m2) | 27.2 (24.2-30.1) | 27.8 (24.4-29.5) |
| Left ventricular ejection fraction < 50% | 28 (15.5%) | 1 (11.1%) |
| NYHA class ≥ III | 26 (14.4%) | 0 (0) |
| Current smoker | 43 (23.8%) | 4 (44.4%) |
| Diabetes | 6 (3.3%) | 1 (11.1%) |
| Hypercholesterolemia | 39 (21.5%) | 1 (11.1%) |
| Hypertension | 113 (62.4%) | 1 (11.1%) |
| Cerebrovascular disease | 12 (6.6%) | 0 (0) |
| Respiratory disease | 30 (16.6%) | 0 (0) |
| Peripheral vascular disease | 13 (7.2%) | 1 (11.1%) |
| Renal dysfunction | 36 (19.9%) | 3 (33.3%) |
| Previous cardiac surgery | 8 (4.4%) | 1 (11.1%) |
| Priority | ||
| Emergency procedure | 154 (85.1%) | 8 (88.9%) |
| Salvage procedure | 7 (3.9%) | 1 (11.1%) |
| Extent of aorta replaced | ||
| Aortic root | 91 (50.3%) | 4 (44.4%) |
| Ascending aorta | 171 (94.5%) | 8 (88.9%) |
| Aortic arch | 76 (42.0%) | 6 (66.7%) |
| Concomitant procedures | ||
| Aortic valve replacement | 105 (58.0%) | 5 (55.6%) |
| CABG | 28 (15.5%) | 1 (11.1%) |
| Operative times | ||
| Circulatory arrest | 45 (34-58) | 33.5 (20.8-49) |
| Cardiopulmonary bypass | 333 (271-392) | 351 (333.5-415.5) |
| Aortic cross-clamp | 180 (131-231) | 196 (139-218) |
CABG=coronary artery bypass grafting; NYHA=New York Heart Association
Patients' outcome.
| Variables | All acute Type A dissections | All femoro-femoral bypasses |
|---|---|---|
| (n=181) | (n=9) | |
| ITU stay (days) | 6 (3-13) | 10 (3-32) |
| Postoperative stay (days) | 14 (9-26) | 21 (14.5-49.5) |
| Acute renal failure | 37 (20.4%) | 3 (33.3%) |
| Deep sternal wound infection | 1 (0.6%) | 0 (0) |
| Reoperation | 40 (22.1%) | 4 (44.4%) |
| Reoperation for bleeding | 22 (12.2%) | 1 (11.1%) |
| CVA | 20 (11.0%) | 1 (11.1%) |
| Paraplegia | 1 (0.6%) | 1 (11.1%) |
| Reoperation for bleeding from the femorofemoral anastomosis | - | 1 (11.1%) |
| Reoperation for tamponade | 9 (4.97%) | 1 (11.1%) |
| In-hospital mortality | 35 (19.3%) | 0 (0) |
CVA=cerebrovascular accident; ITU=intensive therapy unit
| Abbreviations, acronyms & symbols | |
|---|---|
| AKA | = Above-knee amputation |
| ATAAD | = Acute Type A aortic dissection |
| CABG | = Coronary artery bypass grafting |
| CABGX2 | = Two coronary artery bypass graftings |
| CTA | = Computed tomography angiogram |
| CVA | = Cerebrovascular accident |
| CVVH | = Continuous venovenous hemofiltration |
| F | = Female |
| FET | = Frozen elephant trunk |
| ITU | = Intensive therapy unit |
| M | = Male |
| NYHA | = New York Heart Association |
| TOE | = Transoesophageal echocardiography |
| UK | = United Kingdom |
| Authors' roles & responsibilities | |
|---|---|
| TT | Substantial contributions to the conception, design of the work; the acquisition, analysis, interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published |
| AH | Substantial contributions to the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| MS | Substantial contributions to the design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| HE | Substantial contributions to the design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| WE | Substantial contributions to the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| MS | Substantial contributions to the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| DH | Substantial contributions to the conception or design of the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| MK | Substantial contributions to the conception or design of the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| AO | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| MF | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |